{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:39:00Z","timestamp":1793723940358,"version":"4.6.1"},"reference-count":46,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Infect Immun"],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Neisseria meningitidis<\/jats:italic>\n                    serogroup B is a major cause of bacterial meningitis in younger populations. The available vaccines are based on outer membrane vesicles obtained from wild-type strains. In children less than 2 years old they confer protection only against strains expressing homologous PorA, a major, variable outer membrane protein (OMP). We genetically modified a strain in order to eliminate PorA and to overproduce one or several minor and conserved OMPs. Using a mouse model mimicking children's PorA-specific bactericidal activity, it was demonstrated that overproduction of more than one minor OMP is required to elicit antibodies able to induce complement-mediated killing of strains expressing heterologous PorA. It is concluded that a critical density of bactericidal antibodies needs to be reached at the surface of meningococci to induce complement-mediated killing. With minor OMPs, this threshold is reached when more than one antigen is targeted, and this allows cross-protection.\n                  <\/jats:p>","DOI":"10.1128\/iai.00411-07","type":"journal-article","created":{"date-parts":[[2007,7,30]],"date-time":"2007-07-30T20:59:11Z","timestamp":1185829151000},"page":"5434-5442","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":86,"title":["Additive and Synergistic Bactericidal Activity of Antibodies Directed against Minor Outer Membrane Proteins of\n                    <i>Neisseria meningitidis<\/i>"],"prefix":"10.1128","volume":"75","author":[{"given":"Vincent E.","family":"Weynants","sequence":"first","affiliation":[{"name":"GlaxoSmithKline Biologicals, B-1330 Rixensart, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane M.","family":"Feron","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, B-1330 Rixensart, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine K.","family":"Goraj","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, B-1330 Rixensart, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine P.","family":"Bos","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology, Utrecht University, 3584-CH Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe A.","family":"Denoe\u0308l","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, B-1330 Rixensart, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent G.","family":"Verlant","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, B-1330 Rixensart, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Tommassen","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology, Utrecht University, 3584-CH Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian R. A.","family":"Peak","sequence":"additional","affiliation":[{"name":"Institute for Glycomics, Griffith University, Southport QLD 4215, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph C.","family":"Judd","sequence":"additional","affiliation":[{"name":"Division of Biological Sciences, University of Montana, Missoula, Montana 59812"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Jennings","sequence":"additional","affiliation":[{"name":"School of Molecular &amp; Microbial Sciences, University of Queensland, Brisbane QLD 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan T.","family":"Poolman","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, B-1330 Rixensart, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.7.2984-2990.1994"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.180.18.4872-4878.1998"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2004.10.011"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020407"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268898001848"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)60340-5"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(93)90045-Y"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)93086-3"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.28237-0"},{"key":"e_1_3_2_11_2","unstructured":"Invasive Neisseria meningitidis in Europe 2003\/2004. 2006"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90340-9"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00239-004-0194-5"},{"key":"e_1_3_2_14_2","first-page":"81","year":"2001","unstructured":"Frasch, C. E., L. van Alphen, J. Holst, J. T. Poolman, and E. Rosenqvist. 2001. Outer membrane protein vesicle vaccines for meningococcal disease, p. 81-107. In A. J. Pollard and M. C. J. Maiden (ed.), Meningococcal vaccines: methods and protocols. Humana Press, Totowa, NJ.","journal-title":"Meningococcal vaccines: methods and protocols."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/7.4.504"},{"key":"e_1_3_2_16_2","first-page":"67","volume":"14","year":"1991","unstructured":"Fredriksen, J. H., E. Rosenqvist, E. Wedege, K. Bryn, G. Bjune, L. O. Froholm, A. K. Lindbak, B. Mogster, E. Namork, U. Rye, G. Stabbetorp, R. Winsnes, B. Arise, and O. Gloss. 1991. Production, characterization and control of MenB-vaccine \u201cFolkehelsa\u201d: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann.14:67-79.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.1990.tb00697.x"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200310092"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(95)00055-6"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00326-06"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2006.04.011"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1119(93)90348-7"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1006\/mpat.1998.0206"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.185.7.1173"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.11.5664-5675.1999"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.11.6021-6031.2002"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(90)90146-E"},{"key":"e_1_3_2_28_2","unstructured":"Surveillance of bacterial meningitis in Europe 1999\/2000. 2002"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.02.021"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.063"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1006\/mpat.1997.0136"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-695X.2000.tb01494.x"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.5.12.1611"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000147642.85129.05"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00283-3"},{"key":"e_1_3_2_36_2","first-page":"135","year":"2002","unstructured":"Poolman, J. T., C. Feron, G. Desquesne, P. A. Deno\u00ebl, S. Dessoy, K. K. Goraj, D. E. Janssens, S. Kummert, Y. Lobet, E. Mertens, D. Y. Monnom, P. Momin, N. P\u00e9pin, J.-L. Ruelle, J. J. Thonnard, V. G. Verlant, P. Voet, and F. X. Berthet. 2002. Outer membrane vesicles and other options for a meningococcal B vaccine, p. 135-149. In C. Ferreir\u00f3s, M. T. Criado, and J. V\u00e1zquez (ed.), Emerging strategies in the fight against meningitis: molecular and cellular aspects. Horizon Scientific Press, Wymondham, Norfolk, United Kingdom.","journal-title":"Emerging strategies in the fight against meningitis: molecular and cellular aspects."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.68.9.4938-4947.2000"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.12.4642-4652.1995"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1099\/00221287-147-2-250"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.1999.01411.x"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.60.6.2391-2396.1992"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.16.1520"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.61.7.2906-2911.1993"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M302803200"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-695X.2001.tb00534.x"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1078973"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000258697.05341.2c"}],"container-title":["Infection and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.00411-07","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.00411-07","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T01:47:48Z","timestamp":1646444868000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/IAI.00411-07"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["10.1128\/IAI.00411-07"],"URL":"https:\/\/doi.org\/10.1128\/iai.00411-07","relation":{},"ISSN":["0019-9567","1098-5522"],"issn-type":[{"value":"0019-9567","type":"print"},{"value":"1098-5522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11]]},"assertion":[{"value":"2007-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-07-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}